Our look is new. Our purpose is the same. Learn more about our brand evolution.
Project Mercury unites patients, industry, research and clinical communities in groundbreaking initiative from Fulcrum Therapeutics Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics announce the launch of […]
The company’s MyoAAV promises a less toxic way to deliver gene therapies by June Kinoshita, Senior Director of Research and Education Kate Therapeutics, Inc. (KateTx), a San Diego-based biopharma company, […]
by Ken Kahtava, FSHD Society This blog post was originally published here on the Project Mercury website. On 11 May in Leiden, NL, the Project Mercury global task force members met for […]
What can you do to help? When we say that we are embarking on a new era in clinical trials, what do we mean? After all, we have seen previous […]
Our webinar with Dr. Tina Duong remains timely and important for families with FSHD. In it, she focuses on individuals with early-onset FSHD, meaning those who develop symptoms in their […]
